ClinicalTrials.gg
CompletedNCT02951312Updated Apr 30, 2018Results posted

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Glycopyrrolate Inhalation Solution 25mg and Glycopyrrolate Inhalation Solution 75mg in Chronic Obstructive Pulmonary Disease, sponsored by Sunovion Respiratory Development Inc.. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Sumitomo Pharma Co., Ltd..

Enrollment
24th of 24
12 · median 225
Started
2009
with 1 other
Phase 2
7 of 24
none open now
Registered
22nd of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 24th largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 2, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. as a file.
02

Study summary

The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in patients with Chronic Obstructive Pulmonary Disease (COPD). The study was conducted in 12 patients in 2 parts. Part 1 was designed to find the once-a- day GIS dose that produced the highest improvement in lung airflow. Part 2 tested the GIS dose with the highest improvement in lung airflow and a placebo (ie, no drug) delivered by a general purpose nebulizer. The airflow improvements of the same GIS dose were compared between the two nebulizer systems to determine what effect the device had on GIS delivery.

Read the detailed description

In Part I, 12 subjects were randomly allocated to one of 2 cohorts, running in parallel. The 6 cohort 1 subjects received 25 mg and then 200 mg during their treatment periods 1 and 2, respectively. The 6 cohort 2 subjects received 75mg, 500mg, and 1000 mg during their treatment periods 1, 2, and 3, respectively. During Part II of the study, the same 12 subjects from Part I were randomized to receive either 200 mg jet or placebo in a 1:1 ratio.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Emphysema
  • Chronic bronchitis
  • COPD
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 40 through 75 years, inclusive
  2. A clinical diagnosis of according to the GOLD guidelines
  3. Current smokers or ex-smokers with at least 10 pack-year smoking history (e.g., at least 1 pack/day for 10 years, or 10 packs/day for 1 year)
  4. Post-bronchodilator 40-80% of predicted normal
  5. Post-bronchodilator FEV1/FVC ratio \< 0.70
  6. Improvement in FEV1 >12% (minimum 150 mL) following inhalation of ipratropium bromide
  7. Ability to perform reproducible spirometry according to the ATS/ERS guidelines
  8. If female and of , must have had a negative pregnancy test and was not lactating at the Screening Visit, and was using one of the following acceptable means of throughout the study:

    • for at least two years
    • Surgically sterile
    • Oral contraceptives (taken for at least one month prior to the Screening Visit)
    • Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent)
    • Barrier methods (e.g., condoms with spermicide)
    • Intrauterine device (i.e., IUD)
    • Vasectomy of male partner
    • Non-heterosexual life style
  9. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Current evidence or recent history of any disease (other than ) or abnormality in the opinion of the Investigator that would put the patients at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infraction, hypertension, arrhythmia, diabetes, neurological or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities.
  2. Recent history of an exacerbation of airway disease within 3 months or need for increased treatments for COPD within 6 weeks prior to the Screening Visit.
  3. Regular use of daily oxygen therapy.
  4. Use of systemic (e.g., intramuscular or intravenous) within 3 months prior to the Screening Visit
  5. Respiratory tract infection within 6 weeks prior to the Screening Visit
  6. History of tuberculosis, bronchiectasis or other non-specific pulmonary disease
  7. History of urinary retention or bladder neck obstruction type symptoms
  8. History of narrow-angle glaucoma
  9. Current or recent history (previous 12 months) of excessive use or abuse of alcohol
  10. Current evidence or history of abusing legal drugs or the use of illegal drugs or substances
  11. History of or intolerance to aerosol medications
  12. Participation in another drug study where drug was received within 30 days prior to the Screening Visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Glycopyrrolate Inhalation Solution 25mg

    Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 25mg

  • Experimental
    Glycopyrrolate Inhalation Solution 75mg

    Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 75mg

  • Experimental
    Glycopyrrolate Inhalation Solution 200mg

    Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 200mg

  • Experimental
    Glycopyrrolate Inhalation Solution 200mg Jet

    Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 200mg Jet

  • Experimental
    Glycopyrrolate Inhalation Solution 500mg

    Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 500mg

  • Experimental
    Glycopyrrolate Inhalation Solution1000mg

    Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution1000mg

  • Placebo comparator
    Placebo 0.5 mL

    Placebo 0.5 mL via jet nebulizer, once daily

    Drug: Placebo

Interventions

  • DrugGlycopyrrolate Inhalation Solution 25mg

    25 μg oral inhalation via eFlow Nebulizer, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 75mg

    75 μg oral inhalation via eFlow Nebulizer, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 200mg

    200 μg oral inhalation via eFlow Nebulizer, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 200mg Jet

    200 μg oral inhalation via inhalation via jet nebulizer, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 500mg

    500 μg oral inhalation via eFlow nebulizer, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution1000mg

    1000 μg oral inhalation via eFlow nebulizer, once daily

    Also known as: GIS

  • DrugPlacebo

    Placebo 0.5 mL oral inhalation via jet nebulizer, once daily

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Died

    Time frame: 0-47 days

  2. Number of Subjects With Treatment Emergent SAEs

    AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.

    Time frame: 0-47 days

  3. Number of Subjects Who Discontinued Due to AE

    AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.

    Time frame: 0-47 days

  4. Percentage of Subjects With Treatment Emergent AEs

    AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.

    Time frame: 0-47 days

  5. Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study

    Vital signs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study assessment. The clinical significance of each out of normal range vital sign parameter was determined by the investigator during the study.

    Time frame: 30 hrs post dose

  6. Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study

    Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.

    Time frame: day 47 (post studyfollow-up assessment)

  7. Number of Subjects With Clinically Significant ECG Parameters Reported During the Study

    ECGs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study follow-up assessment.

    Time frame: 30hr post dose

  8. Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study

    Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.

    Time frame: post study follow-up assessment (Day 47)

  9. Number of Subjects With Treatment Emergent AEs

    AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.

    Time frame: 0-47 days

Secondary outcomes

  1. Trough FEV1 (Change From Baseline)

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the spirometry value collected at 24 hours post dose within each Treatment Period.

    Time frame: 24hr post dose

  2. Peak FEV1 (Percent Change)

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

    Time frame: 0 to 4hr

  3. Peak FEV1 (Change From Baseline )

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

    Time frame: 0 to 4hr

  4. FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

    Time frame: 0 to 24hr post dose

  5. Cmax Maximum Observed Plasma Concentration

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hours post dose

  6. Tmax Time to Maximum Observed Plasma Concentration

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hours post dose

  7. AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hourr post dose

  8. AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hours post dose

  9. t1/2 Plasma Half-life

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr.

    Time frame: 0 to 12 hours post-dose

07

Results

Posted Apr 30, 2018

Participant flow

Study Part 1
Participant flow — Study Part 1
Milestone25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlacebo
Started6600
Completed6600
Not completed0000
Study Part 2
Participant flow — Study Part 2
Milestone25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlacebo
Started0066
Completed0066
Not completed0000

Outcome measures

PrimaryNumber of Subjects Who Died
Time frame:
0-47 days
Reported as:
Count of participants · Participants
Number of Subjects Who Died
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects Who Died0000000
PrimaryNumber of Subjects With Treatment Emergent SAEs

AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.

Time frame:
0-47 days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent SAEs
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Treatment Emergent SAEs0000000
PrimaryNumber of Subjects Who Discontinued Due to AE

AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.

Time frame:
0-47 days
Reported as:
Count of participants · Participants
Number of Subjects Who Discontinued Due to AE
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects Who Discontinued Due to AE0000000
PrimaryPercentage of Subjects With Treatment Emergent AEs

AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.

Time frame:
0-47 days
Reported as:
Number · percentage of participants
Percentage of Subjects With Treatment Emergent AEs
percentage of participantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Percentage of Subjects With Treatment Emergent AEs33.333.366.733.30.033.316.7
PrimaryNumber of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study

Vital signs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study assessment. The clinical significance of each out of normal range vital sign parameter was determined by the investigator during the study.

Time frame:
30 hrs post dose
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study0000000
PrimaryNumber of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study

Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.

Time frame:
day 47 (post studyfollow-up assessment)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study0000000
PrimaryNumber of Subjects With Clinically Significant ECG Parameters Reported During the Study

ECGs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study follow-up assessment.

Time frame:
30hr post dose
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study0000000
PrimaryNumber of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study

Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study.

Time frame:
post study follow-up assessment (Day 47)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study0000000
PrimaryNumber of Subjects With Treatment Emergent AEs

AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition.

Time frame:
0-47 days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent AEs
ParticipantsGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Number of Subjects With Treatment Emergent AEs2242021
SecondaryTrough FEV1 (Change From Baseline)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the spirometry value collected at 24 hours post dose within each Treatment Period.

Time frame:
24hr post dose
Reported as:
Mean · liters
Trough FEV1 (Change From Baseline)
litersGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Trough FEV1 (Change From Baseline)0.038 ± 0.1570.087 ± 0.0620.138 ± 0.079-0.013 ± 0.098-0.017 ± 0.1680.065 ± 0.072-0.030 ± 0.070
SecondaryPeak FEV1 (Percent Change)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

Time frame:
0 to 4hr
Reported as:
Mean · percent change
Peak FEV1 (Percent Change)
percent changeGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Peak FEV1 (Percent Change)17.12 ± 9.0715.60 ± 4.2022.98 ± 4.9919.28 ± 13.1011.47 ± 6.8616.87 ± 6.836.80 ± 2.91
SecondaryPeak FEV1 (Change From Baseline )

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

Time frame:
0 to 4hr
Reported as:
Mean · liters
Peak FEV1 (Change From Baseline )
litersGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
Peak FEV1 (Change From Baseline )0.212 ± 0.0860.255 ± 0.0680.303 ± 0.0550.233 ± 0.1440.177 ± 0.0610.283 ± 0.0690.120 ± 0.057
SecondaryFEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.

Time frame:
0 to 24hr post dose
Reported as:
Mean · liters
FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)
litersGlycopyrrolate Inhalation Solution 25mgGlycopyrrolate Inhalation Solution 75mgGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mgPlacebo 0.5 mL
FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline)1.59 ± 3.273.10 ± 2.273.19 ± 1.141.35 ± 2.741.53 ± 2.053.08 ± 1.47-0.11 ± 1.89
SecondaryCmax Maximum Observed Plasma Concentration

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hours post dose
Reported as:
Mean · pg/mL
Cmax Maximum Observed Plasma Concentration
pg/mLGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mg
Cmax Maximum Observed Plasma Concentration177.242 ± 61.46975.530 ± 64.950749.872 ± 219.6961534.057 ± 442.581
SecondaryTmax Time to Maximum Observed Plasma Concentration

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hours post dose
Reported as:
Mean · hours
Tmax Time to Maximum Observed Plasma Concentration
hoursGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mg
Tmax Time to Maximum Observed Plasma Concentration.025 ± 0.0880.08 ± 0.0880.25 ± 0.0690.17 ± 0.093
SecondaryAUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hourr post dose
Reported as:
Mean · pg*h/mL
AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration
pg*h/mLGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mg
AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration429.335 ± 192.69926.176 ± 16.1702014.276 ± 609.9114084.763 ± 827.225
SecondaryAUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hours post dose
Reported as:
Mean · pg*h/mL
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
pg*h/mLGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mg
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity563.416 ± 235.41865.013 ± 16.7502491.803 ± 736.4265271.099 ± 1096.862
Secondaryt1/2 Plasma Half-life

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr.

Time frame:
0 to 12 hours post-dose
Reported as:
Mean · hour
t1/2 Plasma Half-life
hourGlycopyrrolate Inhalation Solution 200mgGlycopyrrolate Inhalation Solution 200mg JetGlycopyrrolate Inhalation Solution 500mgGlycopyrrolate Inhalation Solution1000mg
t1/2 Plasma Half-life2.947 ± 1.9960.778 ± 0.4656.298 ± 1.4507.573 ± 1.031

Adverse events

Collected over 0-47 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glycopyrrolate Inhalation Solution 25 μg—0/6 (0%)2/6 (33.3%)
Glycopyrrolate Inhalation Solution75μg—0/6 (0%)2/6 (33.3%)
Glycopyrrolate Inhalation Solution 200 μg—0/6 (0%)4/6 (66.7%)
Glycopyrrolate Inhalation Solution 200μg Jet Nebulizer,—0/6 (0%)2/6 (33.3%)
Glycopyrrolate Inhalation Solution 500μg—0/6 (0%)0/6 (0%)
Glycopyrrolate Inhalation Solution1000mg—0/6 (0%)2/6 (33.3%)
Placebo—0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventGlycopyrrolate Inhalation Solution 25 μgGlycopyrrolate Inhalation Solution75μgGlycopyrrolate Inhalation Solution 200 μgGlycopyrrolate Inhalation Solution 200μg Jet Nebulizer,Glycopyrrolate Inhalation Solution 500μgGlycopyrrolate Inhalation Solution1000mgPlacebo
headacheNervous system disorders1/61/63/61/60/60/61/6
catheter site related reactionGeneral disorders1/60/60/62/60/62/61/6
coughRespiratory, thoracic and mediastinal disorders0/62/60/62/60/62/60/6
nasopharyngitisInfections and infestations0/60/61/60/60/60/60/6
rhinitisInfections and infestations0/60/61/60/60/60/60/6
musculoskeletal discomfortMusculoskeletal and connective tissue disorders0/60/60/61/60/60/60/6

Baseline characteristics

All participants in study

Age, Categorical
Age, Categorical(Participants)25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlaceboTotal
<=18 years00——0
Between 18 and 65 years23——5
>=65 years43——7
Age, Continuous
Age, Continuous(years)25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlaceboTotal
Mean66.2 ± 3.8263.5 ± 8.89——41.67 ± 58.33
Sex: Female, Male
Sex: Female, Male(Participants)25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlaceboTotal
Female32——5
Male34——7
Region of Enrollment
Region of Enrollment(participants)25mg Glycopyrrolate, 200mg Gloycopyrrolate75mg Glycopyrrolate,500mg Glycopyrrolate,1000mg Glycopyrrolate200mg Glycopyrrolate JetPlaceboTotal
United Kingdom66——12
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 8 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Nov 1, 2016
Start
May 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Apr 30, 2018
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02951312
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
May 2009
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Apr 30, 2018
Last update
Apr 30, 2018

Study contacts

Ahmet Tutuncu, MD, PhD
study chair · Elevation Pharmaceuticals, Inc.(now known as Sunovion Respiratory Development Inc.)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion